Kenneth Hitchner, chairman of Board of Directors, Sphere Fluidics, commented: “Sphere Fluidics is changing the face of cell line development. The Cyto-Mine platform has transformed single cell analysis and the productivity of biopharmaceutical discovery, maximising researchers’ productivity in finding rare or valuable cell variants that can lead to a life-changing medicine. I look forward to collaborating with the team as we drive the company forward in this exciting next phase of commercial growth.”
Dr Frank F Craig, CEO, Sphere Fluidics, said: “Ken’s expertise in the Financial Services industry is invaluable, his appointment will become a key asset for our board. He has tremendous experience in positioning companies, facilitating significant fund raises and driving M&A in the Life Sciences arena. This expertise will help us in our future plans for building business value and ultimately exiting via a Trade Sale or IPO.”
For more information about Sphere Fluidics, please visit:
https://spherefluidics.com/.